COMPANY

RespireRx Pharmaceuticals

HQ: Glen Rock, NJ source · respirerx.com ↗ · Mid-Atlantic

Keywords: neurology obstructive sleep apnea attention deficit hyperactivity disorder epilepsy Mild Cognitive Impairment Opiate Induced Respiratory Depression Fragile X Syndrome Autism CX516 CX717 CX1739 CX516 (Ampalex®)

Location: Glen Rock, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)2NIH grants

Funding and NIH signals

NIH award NIH awarded $1.5M (SBIR Phase II 5R44NS143576-02, continuation, notice Sep 14, 2026). NIH RePORTER 5R44NS143576-02 (Sep 14, 2026)
Evidence (1 event)
- Sep 14, 2026 · NIH RePORTER 5R44NS143576-02
  Organization: RESPIRERX PHARMACEUTICALS INC.; City/State: GLEN ROCK, NJ; Project number: 5R44NS143576-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1499869; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Nov 19, 2025 Grant Government grant: $1.5M (total, as published), announced Nov 19, 2025. Source: company release on GlobeNewswire. source ↗
2016-03 Trial start Phase 2: Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia source ↗
Jul 19, 2005 Trial start Phase 2: CX717 in the Treatment of Adult ADHD source ↗
2002-06 Trial start Phase 2: Effects of CX516 on Functioning in Fragile X Syndrome and Autism source ↗
2002-04 Trial start Phase 2: Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment. source ↗

Funding

Last 2 years.

Nov 19, 2025 Government grant: $1.5M (total, as published), announced Nov 19, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT00040443	Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.	Phase 2	Completed	2002-04	2003-08 (actual)
NCT03375021	CX717 in the Treatment of Adult ADHD	Phase 2	Completed	Jul 19, 2005	Jan 10, 2006 (actual)
NCT02735629	Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia	Phase 2	Unknown status (ClinicalTrials.gov)	2016-03	2016-08 (estimated)
NCT00054730	Effects of CX516 on Functioning in Fragile X Syndrome and Autism	Phase 2	Completed	2002-06	Not listed

NIH awards 2

Annual award amounts. Total $3.0M.

Sep 14, 2026 NIH award 5R44NS143576-02 FY2026: $1,499,869 awarded for that fiscal year; activity R44 (SBIR); PI CERNE, ROK; recipient as written: RESPIRERX PHARMACEUTICALS INC., GLEN ROCK, NJ. Development of a novel, preferring p source ↗
Sep 23, 2025 NIH award 1R44NS143576-01 FY2025: $1,499,869 awarded for that fiscal year; activity R44 (SBIR); PI CERNE, ROK; recipient as written: RESPIRERX PHARMACEUTICALS INC., GLEN ROCK, NJ. Development of a novel, preferring p source ↗